Barcelona, Spain – September 15, 2026. ADmit Therapeutics, a biotechnology company specializing in innovative diagnostic solutions for neurodegenerative diseases, is pleased to announce a new collaboration with HVD Life Sciences, a recognized leader in the commercialization of in vitro diagnostic solutions across international markets.
This agreement represents a key milestone in ADmit Therapeutics’ commercial expansion strategy. HVD Life Sciences‘ deep expertise in the diagnostics market, its established distribution networks, and its proven track record in bringing innovative diagnostic technologies to healthcare professionals and laboratories make it an ideal partner to drive the adoption of MAP-AD® across multiple geographies.
Through this collaboration, MAP-AD®, ADmit Therapeutics’ innovative blood-based prognostic test for Alzheimer’s disease dementia, will be introduced into HVD Life Sciences‘ portfolio in precision diagnostics and neurodegenerative disease, significantly broadening its reach to clinical laboratories and healthcare providers.
The collaboration with HVD Life Sciences reflects ADmit Therapeutics’ commitment to introducing and expand innovative technologies that advance personalized and precision medicine in Alzheimer’s disease, while supporting patients and their families in building a more hopeful future.
MAP-AD®: A Novel Blood-Based Prognostic Test
| MAP-AD® is a CE-IVDR certified qualitative in vitro diagnostic test designed to provide a prognosis of progression from Mild Cognitive Impairment (MCI) to dementia due to Alzheimer’s disease in adults aged 55 to 85 years. |
MAP-AD® provides a holistic physiological view by AI-machine learning analysis of specific epigenetic modifications (specifically mitochondrial DNA methylation patterns), genetic risk background (ApoE genotyping), age and neuropsychological status of the patient (CDR-SOB test).
Mitochondrial dysfunction, oxidative stress, and epigenetic remodeling reflect systemic biological distress closely linked to neurodegeneration. By measuring these dynamic epigenetic signatures along with the others patient data, MAP-AD® captures the systemic, multifactorial nature of AD, providing a comprehensive evaluation of disease activity rather than relying solely on protein deposition.
Importantly, the MAP-AD® approach is based on biomarkers that are independent of β-amyloid and tau status, offering a different and complementary perspective on the biological processes associated with progression to Alzheimer’s dementia.
